US-listed company LIXTE Biotechnology launches crypto reserve strategy, plans to allocate 25% of funds to BTC
According to ChainCatcher, Nasdaq-listed company LIXTE Biotechnology has announced that its board of directors has approved a strategic capital allocation plan to acquire cryptocurrencies as part of the company’s funds. The board has also approved allocating 25% of its funds to cryptocurrencies, including Bitcoin and potentially other digital assets as appropriate.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
Data: The total net inflow for the US Solana spot ETF was $1.18 million yesterday.
Twenty One is expected to be listed on the New York Stock Exchange today with the stock code XXI.
Fitch Ratings warns of US banks' cryptocurrency exposure risks and may reassess the ratings of related banks
Trending news
MoreCrypto prices
More
